SEC Form 4 · accession 0001104659-18-071465
BioXcel Therapeutics, Inc. · BTAI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Yocca
Officer — Chief Scientific Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 6, 2018 · 6:04 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001720893
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 3, 2018 | P | 450 | $5.2299 | A | 1,400 | D | |
| Common Stock | Dec 4, 2018 | P | 450 | $5.1973 | A | 1,850 | D |
Table II — derivative securities
No Table II lines on this filing.